gdc

Newsworthy

New Cancer Drugs
FDA NewsNewsworthy
This section provides a brief overview of new medications approved by the FDA between the end of December 2016 and mid-March 2017.
Kisqali a New First-Line Treatment for Patients with Advanced Breast Cancer
FDA NewsNewsworthy
In March 2017, the FDA approved Kisqali (ribociclib), in combination with an aromatase inhibitor, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Keytruda Now Available for Patients with Relapsed Classical Hodgkin Lymphoma
FDA NewsNewsworthy
In March 2017, the FDA approved Keytruda (pembrolizumab), anti-PD-1 immunotherapy, for the treatment of patients with classical Hodgkin lymphoma who are not responding to other therapy or whose disease (relapsed) returned after 3 or more therapies. Keytruda was previously approved for several cancers.
Revlimid Approved for Maintenance Therapy in Patients with Multiple Myeloma After Transplant
FDA NewsNewsworthy
In February 2017, the FDA approved the oral drug Revlimid (lenalidomide) for maintenance (continuing) therapy for patients with multiple myeloma who had autologous hematopoietic stem-cell transplant. Revlimid was previously approved for multiple myeloma and for other types of cancer.
Imbruvica First Non-Chemotherapy Drug Approved for Patients with Marginal Zone Lymphoma
FDA NewsNewsworthy
In January 2017, the FDA approved Imbruvica (ibrutinib) for the treatment of patients with marginal zone lymphoma who need systemic therapy and have received at least 1 previous anti-CD20-based therapy.
Opdivo a New Treatment Option for Patients with Advanced or Metastatic Bladder Cancer
FDA NewsNewsworthy
In February 2017, the FDA approved Opdivo (nivolumab), anti-PD-1 immunotherapy, for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Rubraca a New Oral Treatment Approved for Patients with Advanced Ovarian Cancer
FDA NewsNewsworthy
In December 2016, the FDA approved Rubraca (rucaparib), a new oral PARP inhibitor, for the treatment of advanced ovarian cancer with a BRCA mutation (alteration) in patients who had received at least 2 chemotherapies.
Page 4 of 5
Results 31 - 40 of 45

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country